Skip to main content
Premium Trial:

Request an Annual Quote

Laboratoire Cerba, Pathoquest Ink Licensing Agreement for Metagenomic Blood Test

NEW YORK (GenomeWeb) – Laboratoire Cerba, a member of the Cerba Healthcare group, and Pathoquest announced this week a licensing agreement for the iDTect Blood test for use in the precision diagnosis of infectious diseases.

IDTect is a metagenomic test developed by Pathoquest, a spinout of Institut Pasteur, that uses next-generation sequencing technology in combination with preanalytical methods and bioinformatics technologies. The test can identify more than 1,200 clinically relevant bacteria and viruses from a single blood sample and can deliver results for use by clinicians and microbiologists within 48 hours.

The agreement allows Laboratoire Cerba, a laboratory that specializes in medical biology testing, to run patient samples for the iDTect test on its genomics platform in Saint-Ouen L’Aumône. The licensing agreement exclusively covers the countries of France, Belgium, and Luxembourg. The deal also includes a non-exclusive license for use of the test in select countries in Europe, the Middle East, and Africa, and permits Pathoquest to introduce the test directly to microbiology laboratories within specific reference hospitals.

Additional terms of the deal were not disclosed.

In a statement, Jean François Brepson, CEO of Pathoquest, said, "Not only does [the agreement] confirm the clinical utility of our test for the clinical diagnosis of infectious diseases, it is also a significant step in our strategy to launch the iDtect Blood test since Cerba laboratories’ large network enables us to extend access to our innovative test to a larger number of patients who have a genuine need for [a] more reliable option for identifying pathogens responsible for their infections."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.